Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Carter Berezay who wrote (768)	6/13/2001 9:27:46 AM
From: Carter Berezay	Read Replies (2) \| Respond to of 792

NEW YORK, June 13 (Reuters) - Eli Lilly and Co. (NYSE:LLY - news) slumped in pre-open trading on Wednesday after it said that U.S. regulators extended their review date for its application for a treatment of sepsis. Eli Lilly said the action came because regulators needed more time to look at what the drug maker called ``a new class of drug for a complex disease state.'' Eli Lilly's shares fell to $82.50 on the Instinet electronic brokerage system from Tuesday's close of $86.50. Makes MBI-226 look a lot better. Eli Lilly is years behind with their cure. Carter B.